carbohydrate-bas approach scd hematolog cancer
initi coverag buy rate price target
late stage product partnership larg cap pharma
compani initi coverag inc
buy rate price target base posit outlook
compani pipelin includ lead candid rivipansel
pan-selectin inhibitor phase develop treatment
focus develop glycomimet drug address unmet
medic need diseas carbohydr biolog play
import role rivipansel develop
rate discuss agreement compani
also wholly-own product uproleselan e-selectin inhibitor
target endotheli cell intend interrupt bone marrow
cellular adhes leukem cell upcom catalyst
includ initi uproleselan phase phase nci/
data scd voc patient expect proof-of-concept
uproleselan m-protein data multipl myeloma mm patient expect
also anticip enrol complet earli
rivipansel phase trial believ could posit impact stock
follow previou extens enrol timelin
neg impact stock believ compani
two late stage product one licens current
under-valued believ stock bought ahead
potenti catalyst
differenti approach sickl cell diseas rivipansel take
novel approach design disrupt attach
cell activ endothelium cell restor normal blood flow
patient scd allevi voc pain attack lack oxygen
deliveri tissu often result hospit treatment includ
use opioid phase reset trial rivipansel scd voc
anticip enrol approxim patient
larger phase trial phase data impress
opinion sever endpoint trend posit statist
signific phase studi conduct spa fda
includ sever chang review report believ
phase design lead posit data context phase
compani report hour reduct actual hospit discharg
posit trend statist signific statist
signific reduct mean cumul iv opioid analges use
observ compar placebo believ rivipansel
on-demand treatment scd voc develop remind
investor novarti nv rate acquir selexi novemb
approxim obtain phase anti-p-
selectin antibodi develop scd voc
novarti drug biolog rivipansel small molecul
approv could price advantag conserv estim
rivipansel price per treatment assum
patient hospital-visit per year alon one cours
therapi repres estim market opportun
definit distribut analyst rate analyst certif disclosur pleas refer page report
impress deal octob enter agreement grant exclus
world-wide licens develop commerci product contain rivipansel run phase reset trial
scd voc patient august state trial approxim enrol
regulatori mileston respons regulatori approv process world-wide commerci
million regulatori mileston possibl next potenti mileston accept nda
fda accept file ema estim fda mileston payment could ema
mileston payment
develop mileston also develop mileston million remain includ first commerci
sale first commerci sale europ
commerci mileston commerci mileston million possibl
royalti agreement also stipul receiv tier royalti rang low
doubl digit low teen includ valu valuat rivipansel deal
uproleselan could use sever aml patient popul uproleselan e-selectin inhibitor develop
treat patient aml well mm target endotheli cell intend interrupt bone marrow cellular adhes
blood cancer cell therebi interf cancer cell surviv pathway present final analysi
complet phase trial uproleselan patient r/r newli diagnos aml mrd-neg remiss
occur evalu patient r/r aml evalu patient newli diagnos aml uproleselan
ad standard chemotherapi regimen r/r aml cohort recommend phase dose cr/cri
rate cr/complet remiss incomplet blood count recoveri median os month histor os
character month patient popul newli diagnos aml cohort recommend phase
dose cr/cri rate median os month event free surviv ef month uproleselan
receiv fda track design adult r/r aml elderli aml patient age year older well
breakthrough therapi design orphan drug design aml grant fda european union
last month dose first patient pivot phase trial evalu uproleselan efficaci safeti r/r
aml patient primari endpoint os compani collabor nation cancer institut nci
nci-sponsor phase trial newli diagnos aml patient accept fit chemotherapi addit hovon
haemato oncolog foundat adult netherland sponsor phase trial newli diagnos aml patient
unfit chemotherapi focus exclus europ nci hovon trial expect start enrol
believ divers address aml patient could provid comprehens assess uproleselan
impact within aml indic estim uproleselan aml could gener almost million revenu
uproleselan also develop mm phase trial combin velcade-bas chemotherapi mm
consid curabl current treatment believ uproleselan approv potenti introduc
novel clinic signific option multipl myeloma patient anoth product small molecul dual inhibitor
e-selectin develop target immun modul cancer phase data expect earli
estim approv uproleselan could gener almost million sale mm indic
valuat base price target probability-adjust forecast uproleselan aml mm well rivipansel
scd voc use net present valu revenu forecast appli po aml phase
po mm phase po scd voc phase price/sal multipl aml mm
total estim uproleselan valu valu rivipansel estim year-end net cash
per share arriv price target p/ multipl in-line peer rang
glycomimet finish cash equival compani anticip cash
equival releas uproleselan data r/r aml patient anticip expect
includ compani receiv possibl mileston payment result rivipansel collabor
interim estim uproleselan aml patient reach market gener sale million year
million estim uproleselan mm patient reach market gener sale
million year million rivipansel scd voc patient estim product reach
market gener million mileston royalti payment year million
total royalti remind investor novarti nv rate acquir selexi novemb approxim
includ up-front acquisit mileston payment obtain phase anti-p-selectin antibodi
develop scd voc assign valu potenti preclin earli stage selectin galectin product
view potenti upsid call option
risk commerci regulatori develop manufactur financi liabil intellectu properti
initi coverag stock glycomimet buy rate price target
compani headquart rockvil md approxim employe locat
mid-decemb commenc oper may complet ipo januari
stock list exchang focus develop glycomimet
drug address unmet medic need diseas carbohydr biolog play import role
molecul mimic carbohydr structur involv biolog process compani
leverag expertis carbohydr chemistri creat innov therapeut product inflamm
cancer infect glycomimet lead product rivipansel pan-selectin inhibitor phase
develop treatment sickl cell diseas scd vaso-occlus crisi voc selectin
adhes protein bind carbohydr inflamm progress hematolog disord
rivipansel design disrupt tether adher cell activ endothelium cell restor
normal blood flow allevi voc octob enter agreement
grant exclus world-wide licens develop commerci product contain
rivipansel licens agreement requir use commerci reason effort
develop pursu approv commerci rivipansel scd turn
elig receiv mileston payment tier royalti leadership phase
reset trial current evalu efficaci safeti rivipansel treatment voc patient
hospit scd anticip phase enrol complet rivipansel scd voc patient
earli expect top-lin data
uproleselan specif selectin inhibitor develop acut myeloid leukemia
aml well multipl myeloma mm patient uproleselan e-selectin inhibitor target
endotheli cell intend interrupt bone marrow cellular adhes blood cancer cell
therebi interf cancer cell surviv pathway american societi hematolog
annual meet decemb compani present final analysi phase trial
uproleselan patient aml includ improv remiss rate observ relapsed/refractor r/r
aml newli diagnos aml patient treat uproleselan along mitoxantron etoposid
cytarabin induct chemotherapi respect uproleselan ad chemotherapi
well toler low oral mucos rate high remiss rate high measur residu
diseas mrd neg transplant rate display encourag surviv outcom phase
uproleselan studi underway r/r older treatment-nav aml patient decemb
uproleselan phase result show antagon e-selectin transmembran
glycoprotein improv efficaci safeti chemotherapi r/r newli diagnos older aml
patient primari endpoint safeti assess frequenc sever related advers
event time-frame day uproleselan found safe ad salvag
chemotherapi standard induct chemotherapi high remiss rate determin
durabl r/r newli diagnos aml patient low induct mortal promis surviv
outcom group addit uproleselan track design orphan drug
design aml breakthrough therapi design grant may novemb
glycomimet dose first patient global phase trial uproleselan r/r aml patient
compani target top-lin data primari endpoint overal surviv os trial
design provid readout possibl approv submiss us europ
compani initi phase multipl ascend dose-escal mad trial uproleselan
defin popul mm patient adjunct standard care soc chemotherapi initi top-
line data like avail phase trial multi-cent open-label dose escal trial
measur efficaci safeti pharmacokinet uproleselan combin chemotherapi
among patient diagnos mm respond well standard chemotherapi mm
consid curabl current
proteasom inhibitor immunostimulatori cytolyt antibodi thalidomid analogu nitrosourea
hdac bisphosphon dna replic inhibit therefor believ uproleselan approv
potenti introduc novel clinic signific therapi mm patient
glycomimet selectin inhibit platform also produc small molecul dual inhibitor
treatment
e-selectin chemokin receptor express variou cancer includ
hematolog cancer solid tumor intend mobil tumor cell sensit
chemotherapi alter tumor microenviron enhanc immun respons
phase trial e-selectin antagon complet detail anticip
announc earli
glycomimet finish cash equival compani anticip
cash equival releas uproleselan data r/r aml patient
anticip expect includ compani receiv possibl mileston
payment result rivipansel collabor interim estim
uproleselan aml patient reach market gener sale million year
million estim uproleselan mm patient reach market
gener sale million year million rivipansel scd voc
patient estim product reach market gener million mileston
royalti payment year million total royalti
phase clinic trial program updat
uproleselan glyc-phas r/r aml global territori enrol
initi nci/hovon consortium-fund frontlin aml trial
uproleselan proof-of-concept m-protein data multipl myeloma
project submiss fda approv scd voc patient
compani report wainwright research
bullish glycomimet import reason list
rivipansel develop present possibl novel on-demand therapi scd voc
sickl cell diseas character group inherit red blood cell disord abnorm
sickl hemoglobin hemoglobin hb interfer normal oxygen transport result relat
complic includ organ damag affect individu inherit two abnorm hemoglobin gene
patient two hemoglobin gene display common sever manifest diseas
known sickl cell anemia common exampl sickl cell diseas includ hemoglobin scd
hemoglobin thalassemia scd abnorm hemoglobin beta-chain form strand within
induc compromis sickl cell shape sickle-shap red blood cell travel throughout
circulatori system becom stuck blood vessel wall imped blood flow oxygen
deliveri tissu
addit chronic pain observ adolesc adult scd pain attack crise occur
result lack oxygen deliveri tissu often result need hospit treatment
report discomfort level rival post-surg pain sickl cell addit less abl physic
chang shape burst reduc number circul rbc possibl result anemia
 life expect rang year old scd patient hematopoiet stem
cell transplant hsct cure scd mani patient rel well-
match donor may frail undergo transplant altern life-long
treatment reli upon reduc diseas symptom avoid complic approxim
american scd roughli everi african american children born scd accord
nation institut nih preval sickl cell anemia major market includ
 europ saudi arabia brazil roughli approxim children
born scd global year accord american societi hematolog
outsid hsct therapi patient blood transfus treat anemia diseas treatment focus
health mainten prevent complic scd due compromis spleen function
infect prevent particularli suscept infant children address penicillin
daili antibiot patient least five year age chronic acut pain manag
rang over-the-count pain medicin need outpati emerg room care
unpredict voc use prescript pain medic includ opioid sickl rbc
along inflammatori factor produc selectin adhes molecul bind immun cell
endothelium trap sickl rbc circul induc voc extrem pain result sickl
rbc block vascular blood flow effect caus tissu damag result acut pain
standard voc therapi includ transfus rehydr manag patient oxygen
level pain manag use nsaid high dose acetaminophen duloxetin
gabapentin amitriptylin opioid endari fda-approv l-glutamin oral powder use
reduc sickl cell crise patient age fda-approv hydroxyurea origin
approv adult patient target fetal hemoglobin approv sickl cell
anemia patient age older hydroxyurea myelosuppress agent use reduc pain
episod frequenc rais hbf hemoglobin level scd patient also found
reduc occurr sever acut chest syndrom event side effect includ nausea
vomit diarrhea drowsi risk clinic stroke cognit impair also close
monitor scd patient well suscept physic overexert relat reduc
glycomimet lead develop candid rivipansel pan-selectin antagonist interfer
attach cell vessel endothelium restor blood flow allevi voc novel
approach base reduc selectin protein-carbohydr adhes activ inflamm
associ scd voc phase reset trial rivipansel scd voc anticip complet
enrol earli top-lin data expect enrol complet expect
move back account logist challeng dose patient within
present hospit studi conduct collabor partner
august advis glycomimet enrol reach approxim
complet phase trial design discuss model phase data four
time size phase studi conduct special protocol assess spa
fda rivipansel on-demand treatment scd voc develop
awar
phase reset trial evalu efficaci safeti rivipansel treatment voc
hospit patient scd trial multicent double-blind placebo-control
random parallel group studi estim enrol approxim patient
experiment arm rivipansel deliv intraven everi hour dose maximum
subject age weigh kilogram receiv initi dose mg
rivipansel follow dose mg everi hour subject year old subject
weigh kilogram less receiv weight-bas dose mg/kg mg/kg rivipansel
maximum mg follow dose mg/kg rivipansel maximum mg everi
hour accord protocol patient compar placebo arm receiv placebo infus
intraven everi hour dose maximum primari endpoint time readi
discharg defin differ readi discharg date time
first infus start date time assess occur everi four hour daili
durat patient hospit anticip averag five day view real-tim
readi discharg rigor metric phase analysi includ median time
discharg variabl doctor avail patient pick-up could influenc actual
patient discharg time measur rivipansel impact voc hospit view patient
readi discharg meaning clinic endpoint studi run spa
believ fda well secondari endpoint addit includ time discharg cumul iv
opioid consumpt time load dose rivipansel discharg time discontinu
iv opioid cumul iv opioid consumpt within first hour post-load dose rivipansel
percent subject re-hospit voc within three day discharg disclos
inform concern power reset studi would expect delta hour
primari endpoint time readi discharg could approv result
phase trial patient age year old hospit scd voc random
double-blind placebo-control studi efficaci safeti pharmacokinet rivipansel patient
receiv rivipansel placebo addit receiv usual treatment pain crisi primari
endpoint measur reduct time resolut voc day resolut includ
metric pain score actual time leav hospit secondari endpoint measur
safeti studi day post last dose pharmacokinet includ half-lif
concentr rivipansel blood urin marker inflamm cell sticki
blood day post last dose median time resolut voc reduc
day follow rivipansel treatment time resolut hour rivipansel group versu
hour placebo although statist signific secondari endpoint
improv includ reduct mean cumul iv opioid analges use compar
placebo median time discharg reduc hour also statist
signific howev better data captur phase trial increas size
trial believ readi discharg chang possibl statist signific
addit advers event consid relat treatment found compar
rivipansel placebo group common treatment emerg includ nausea
constip headach acut chest syndrom common seriou ae re-hospit
voc sae rate rivipansel placebo group patient discontinu
drug group account day improv reason
figur rivipansel phase opioid
averag annual cost adult patient scd averag cost
hospit stay scd patient treat voc therefor shorten
stay econom import payer conserv estim rivipansel price
per treatment assum patient-visit per year alon one cours
therapi repres estim market opportun believ price estim
low orphan drug market outsid potenti larger ex-u
expans opportun saudi arabia market approxim address patient
well approxim patient brazil estim patient throughout eu
market also upsid beyond estim singl voc episod per patient per year
includ emerg depart outpati set rivipansel present
infus time could allow dose administ er set addit expand
enrol earli top-lin data expect follow fda file late earli
expect potenti fda file accept earli approv along first
commerci sale file accept us eu correspond mileston payment clinic
develop partner first commerci sale project half regulatori
mileston nda accept would paid glycomimet day follow file
decemb novarti nv rate present post hoc analysi phase
sustain studi anti-p-selectin monoclon antibodi crizanlizumab total studi
compar p-selectin inhibitor crizanlizumab placebo scd patient compani report
crizanlizumab abl significantli reduc frequenc voc lead healthcar
util compar placebo overal ae sae incid compar
crizanlizumab placebo group hoc analysi publish american journal hematolog
includ data patient patient treat crizanlizumab
patient placebo patient treat crizanlizumab experi voc compar
placebo vs evalu patient histori least two voc year
lead trial select crizanlizumab group display voc compar placebo
analysi multipl subgroup patient two four event prior year
experi voc vs placebo patient five ten event
prior year experi voc vs placebo hbss genotyp
patient experi voc vs placebo concomit
hydroxyurea patient experi voc vs placebo
safeti concern emerg post hoc analysi anticip possibl file
novarti scd
novarti previous present phase sustain data crizanlizumab show delay time
first sickl cell pain crisi approxim two-fold greater patient versu placebo subgroup
scd adult patient endotheli cell platelet up-regul p-selectin character
part develop scd voc phase sustain studi evalu low-dos crizanlizumab
bodi weight high-dos crizanlizumab bodi weight placebo administ
intraven time week period scd patient sickl cell-rel pain crise
high-dos crizanlizumab result lower median rate crise per year versu placebo
well longer median time first crisi compar placebo month vs month
high-dos crizanlizumab cohort addit display longer median time second
crisi versu placebo month vs month lower median rate
uncompl crise per year compar placebo addit high-dos crizanlizumab
patient receiv hydroxyurea show annual crise rate lower placebo lower
patient receiv hydroxyurea therapi
regard gene therapi follow strateg collabor crispr
crsp rate vertex pharmaceut fein buy compani develop
investig gene-edit autolog hematopoiet stem cell therapi treatment
scd octob fda lift clinic hold pend resolut question
fda accept ind crispr vertex previous obtain approv
clinic trial applic multipl countri ex-u -thalassemia scd
develop compani current remain track decemb initi phase
clinic trial scd patient believ rivipansel remain yet differenti pan-selectin
inhibitor intend on-demand scd voc treatment
altern approach clinic develop scd includ global blood inc
chattopadhyay buy oral once-daili candid voxelotor current conduct
phase studi double-blind random placebo-control multicent studi voxelotor
administ oral scd patient primari outcom measur chang hemoglobin hb
baselin week proport particip increas hb baselin
week voxelotor affect sickl hemoglobin maintain hemoglobin oxygen state act
hb polymer inhibitor prevent format associ rigid hemoglobin chain
decemb global blood disclos posit regulatori feedback enabl compani
file acceler approv base outcom studi hemoglobin primari
endpoint addit global blood commit least one post market studi organ
preserv primari endpoint detail still evolv post market studi could
leverag voxelotor abil reduc blood viscos henc use transcrani doppler radar tcd
demonstr declin tcd veloc expect surrog concomit reduct
stroke risk pediatr could broad label voxelotor upon acceler approv
patient older
decemb present efficaci safeti result patient follow
week part studi well cohort data -kid studi
updat week data underscor voxelotor abil increas hemoglobin decreas marker
associ hemolysi without increas pain crisi importantli hemoglobin increas come
without erythropoietin increas impli voxelotor potenti normal life span
day scd patient approxim day healthi individu evalu efficaci
safeti analysi patient week voxelotor patient
voxelotor patient achiev hemoglobin increas week compar
placebo patient voxelotor show hemoglobin increas mean
week baselin clinic meaning anemia improv importantli patient
part stabl hydroxyurea therapi suggest benefit voxelotor like
synergist hydroxyurea numer fewer voc episod well lower voc
incid rate/person/year voxelotor patient compar placebo
august announc exclus world-wide licens agreement roch rhhbi rate
develop inclacumab human monoclon antibodi p-selectin treatment scd voc
term respons inclacumab develop manufactur commerci
world-wide bind p-selectin mechan inclacumab intend reduc adhes
endotheli cell platelet involv develop voc roch previous discontinu
inclacumab program coronari arteri diseas phase addit inclacumab gbt
portfolio compliment voxelotor voxelotor affect sickl hemoglobin maintain hemoglobin
oxygen state act inhibit hb polymer prevent associ rigid hemoglobin
chain format inclacumab mechan action close reflect rivipansel program
inclacumab specif monoclon antibodi p-selectin rivipansel character
pan-selectin inhibitor scd voc intend leverag inclacumab clinic safeti data
compil roch submiss ind inclacumab anticip
gene therapi scd also explor bluebird bio inc rate specif
regard candid lentiglobin insert function human beta-globin gene ex vivo
patient hematopoiet stem cell subsequ autolog stem cell transplant
patient bloodstream infus amino-acid substitut beta-globin gene lentiglobin
design direct anti-sickl properti could potenti address scd diseas state along
compani relat clinic investig -thalassemia studi
specif address sever scd on-going open-label single-cent phase studi
evalu safeti efficaci lentiglobin treatment patient transfusion-depend
thalassemia tdt sever scd case studi first patient sever scd treat
lentiglobin gene therapi remain free clinic symptom month follow lentiglobin treatment
produc hba threshold anti-sickl hb anti-sickl hemoglobin
level maintain month follow case studi patient publish new
england journal medicin
bluebird bio on-going open-label phase multicent trial assess lentiglobin gene
therapi efficaci safeti sever adult scd patient decemb data present
seven patient greater three month post-treat lentiglobin group total hemoglobin
level stabl month three reach rang patient six month post
treatment lentiglobin treatment-deriv hemoglobin hba equal exceed hb level group
patient six month follow treatment report voc event group nine month post-
treatment lentiglobin observ interim result present eha meet june
show four six patient group amend protocol greater equal three month
follow produc hba three month one patient produc hba
total hemoglobin level six month patient nine month follow
group amend protocol respect produc hba total hemoglobin
hba nine month follow hba total hemoglobin hba month
follow long-term data seven patient initi studi cohort group origin protocol two
year follow display steadi level lentiglobin vector hba median total
hemoglobin last studi visit g/dl overal safeti profil report gener
consist myeloabl condit
octob licens agreement establish
grant exclus world-wide licens develop commerci product contain
rivipansel along chemic modif improv accord agreement
develop pursu regulatori approv commerci rivipansel scd exchang
up-front payment mileston payment includ dose first patient
phase trial mani two indic first domest select european commerci
sale upon reach specif regulatori mileston european approv
two indic reach annual net sale threshold made
mileston payment may recogn revenu remain
mileston payment made glycomimet june result dose first
patient phase clinic trial payment made tier royalti
percentag also possibl rang low doubl digit low teen net world-wide sale
licens product addit research servic agreement univers
basel must pay univers futur mileston royalti payment made
relat rivipansel result total mileston licens fee record within research
develop expens paid univers record year end decemb
subsequ payment follow two year issu patent rivipansel method
use anticip expir public state rivipansel could
blockbust greater drug agre believ rivipansel worth per share
valuat
uproleselan offer potenti differenti approach aml progress
acut myeloid leukemia aml type cancer origin bone marrow character
prolifer abnorm white blood cell classif blast threshold
diagnosi aml blast blood bone marrow aml mainli afflict older peopl rare
occur age averag aml patient year old american cancer
societi ac estim new case aml diagnos
case estim world-wide ac project aml may respons
death almost expect adult standard treatment
typic split induct therapi treatment achiev complet remiss
consolid therapi treatment prevent recurr aml achiev complet remiss
induct therapi younger patient main option consolid therapi intens
chemotherapi allogen autolog stem cell transplant treatment aml consist
chemotherapi vidaza azacitidin sometim along target therapi drug
appropri depend upon condit age patient common chemotherapi regimen
continu infus cytarabin seven day three day usual daunorubocin
doxorubicin idarubicin therapi hematopoiet stem cell transplant hsct follow
chemotherapi possibl mylotarg gentuzumab ozogamicin antibody-drug conjug
also use along chemotherapi patient aml newli diagnos r/r
aml patient age two year old fludarabin cytarabin idarubicin fai repres
anoth regimen aml patient salvag regimen aml includ mitoxantron etoposid
cytarabin chemotherapi r/r aml patient
surviv relaps rate aml typic depend cytogenet intermediate-risk patient
five-year surviv rate around relaps rate around aml one deadliest cancer
median overal surviv r/r patient less four month surviv rate
newli diagnos patient month seen current avail therapi
glycomimet approach target diseas state selectin protein-carbohydr bind selectin
antagonist present differenti approach aml patient combin chemotherapi
uproleselan specif selectin inhibitor develop design block bone
marrow cellular adhes molecul e-selectin bind blood cancer cell thu interrupt
cancer cell surviv pathway selectin adhes protein bind carbohydr
inflamm progress hematolog disord character p-selectin
type e-selectin associ endotheli cell l-selectin express lymphocyt p-
selectin associ platelet endotheli cell preclin studi uproleselan shown
prevent movement tumor cell bone marrow disrupt cell adhes mediat drug
resist reduc chemotherapi associ toxic protect normal hematopoiet stem cell
approv therapi aml furthermor includ pharmaceut livnat neutral vyxeo
liposom combin topoisomeras inhibitor daunorubicin nucleosid metabol
inhibitor cytarabin therapi indic newli diagnos adult aml patient aml patient
myelodysplasia-rel chang mutat isocitr dehydrogenas affect
approxim aml patient tibsovo ivosidenib approv earlier
inhibitor adult r/r aml suscept mutat determin test idhifa enasidenib
similarli approv treatment adult r/r aml patient mutat detect
test tabloid thioguanin purin analogu interfer nucleic acid biosynthesi
approv acut non-lymphocyt leukemia rydapt midostaurin kinas inhibitor approv
treatment newli diagnos aml mutation-posit combin standard
cytarabin daunorubocin induct cytarabin consolid novemb three
fda approv treatment aml fda approv xospata gilteritinib alpmi rate
treatment adult patient r/r aml mutat detect fda-approv test
fda grant acceler approv venclexta venetoclax rate combin
azacitidin decitabin low-dos cytarabin treatment newly-diagnos aml adult
age year older comorbid preclud use intens induct
chemotherapi fda addit approv daurismo glasdegib rate combin
low-dos cytarabin ldac newly-diagnos aml patient year old older
comorbid preclud intens induct chemotherapi
present final analysi complet phase trial uproleselan
patient r/r newli diagnos aml phase trial assess safeti efficaci escal
dose uproleselan combin mitoxanthron etoposid cytarabin r/r aml
patient phase ad elderli newli diagnos aml patient cohort receiv uproleselan
cytarabin idarubicin induct chemotherapi clinic outcom analysi indic greater
evalu r/r newli diagnos aml patient respect achiev stringent level
measur residu diseas mrd neg translat extend os rel match
histor control r/r patient least e-selectin ligand express baselin
correl prolong surviv uproleselan treat patient contrast expect
r/r aml patient greater e-selectin ligand express leukem blast would
poorli believ encourag observ possibl suggest biolog activ stage
test detect level e-selectin ligand express observ leukem cell everi test
patient support biolog relev e-selectin ligand express leukem stem cell
correl leukem blast e-selectin ligand express bone marrow blast consist
propos chemoresist mechan
achiev mrd-neg remiss occur evalu patient r/r aml
evalu patient newli diagnos aml uproleselan ad standard
chemotherapi regimen r/r aml cohort recommend phase dose
cr/cri rate cr/complet remiss incomplet blood count recoveri median os
month ci remind compar histor control os character
month newli diagnos aml cohort recommend phase dose cr/cri
rate median os month ci reach event free surviv ef
month context compar histor control ef month
repres lower risk patient popul evalu trial view combin
improv remiss rate report low rate mucos strong posit program
momentum build phase phase trial uproleselan aml patient addit
compani highlight potent e-selectin antagonist novel dual-funct
e-selectin inhibitor reflect potenti divers opportun within selectin
figur uproleselan phase r/r aml
figur uproleselan phase newli diagnos aml
decemb phase result antagon e-selectin transmembran
glycoprotein uproleselan report improv efficaci safeti chemotherapi r/r
newli diagnos older aml patient phase arm compris uproleselan combin
chemotherapi r/r aml subject year older phase arm compris
uproleselan combin r/r aml subject year older phase arm
compris uproleselan combin cytarabin idarubicin regimen newli
diagnos aml subject year older primari outcom measur safeti assess
frequenc sever related advers event time-frame day secondari
outcom measur includ time versu plasma concentr profil uproleselan time frame
day overal respons rate time respons dor event-fre surviv overal surviv
uproleselan found safe ad salvag chemotherapi standard induct
chemotherapi uproleselan ad chemotherapi display high remiss rate determin
durabl r/r newli diagnos aml patient low induct mortal promis surviv
outcom group r/r aml patient median os month median dor
month patient proceed hematopoiet stem cell transplant
hsct median follow month older newli diagnos aml patient median os
month median dor month median event free surviv month total
patient proceed hsct median follow month
figur uproleselan phase r/r aml
figur uproleselan phase newli diagnos aml
uproleselan receiv fda track design adult r/r aml elderli aml patient age
year older well orphan drug design aml grant fda
european union breakthrough therapi design grant may fda
novemb dose first patient pivot phase trial evalu
uproleselan efficaci safeti r/r aml patient trial target enrol adult patient
across site north america europ australia top line readout target
major studi site locat within primari endpoint overal surviv defin
time random death caus analysi os stop
patient progress hsct elig criteria consist patient age year old either
primari r/r first second relaps aml elig intens salvag treatment one
prior hsct treatment singl induct cycl compar uproleselan plu fludarabin
cytarabin idarubicin fai fai respect consolid compris
hidac/idac hidac/idac along subsequ patient follow per protocol trial design
inform guidanc receiv regulatori agenc secondari endpoint includ sever
mucos incid remiss rate assess possibl inclus product label
three cycl evalu uproleselan plu high-dos
phase glycomimetics-sponsor r/r aml trial initi across investig site
expans europ canada australia studi well-pow demonstr overal
surviv improv median os remain approxim use therapi
glycomimet anticip comprehens data packag util os metric glycomimetics-
sponsor phase supplement two addit uproleselan collabor announc earlier
februari collabor announc hovon haemato oncolog
foundat adult netherland hovon-sponsor phase trial newli diagnos
aml patient unfit chemotherapi plan exclus europ may
collabor announc nation cancer institut nci-sponsor phase trial
newli diagnos aml patient accept fit chemotherapi strateg collabor
add credibl uproleselan platform aml opinion could stand provid
substanti data uproleselan across aml indic lower cost hovon- nci-
sponsor trial anticip begin enrol
glycomimet clinic develop strategi gener uproleselan data across rang
aml care phase glycomimetics-sponsor trial design r/r aml patient
phase hovon-sponsor trial plan approxim newli diagnos aml patient
unfit chemotherapi phase nci-sponsor trial plan interim analysi approxim
newli diagnos aml patient year old fit chemotherapi refer newli
diagnos older aml patient fit intens chemotherapi report benchmark event-fre
surviv month therapi design month vyxeo versu therapi newli
diagnos aml patient unfit intens chemotherapi overal respons rate benchmark
report decitabin versu patient choic azacitidin versu convent care
nci-sponsor trial run cooper research develop agreement
crada nci agreement sign may collabor
nci allianc clinic trial oncolog test uproleselan ad standard
regimen newli diagnos elderli aml patient suitabl intens chemotherapi nci may
fund addit research includ pediatr aml patient well preclin experi
note across three aml studi conduct r/r aml patient newli diagnos aml
patient unfit chemotherapi newli diagnos aml patient fit chemotherapi respect
differ endpoint relev patient group r/r aml studi conduct
glycomimet focus overal surviv best character possibl uproleselan impact
patient respons believ r/r aml patient popul os endpoint could
greatest relev possibl approv reimburs payer hovon-sponsor trial
newli diagnos aml patient unfit chemotherapi assess complet remiss rate respons
three cycl treatment comparison nci-sponsor trial newli diagnos aml patient
fit chemotherapi evalu event-fre surviv includ plan interim analysi base
event-fre surviv first patient enrol trial believ divers
aml patient respect population-depend endpoint across studi could provid
comprehens assess uproleselan impact within aml indic
addit development approach aml includ car-t therapi well donor-deriv nk cell
celyad cyad white buy exampl record world first complet respons r/r aml
patient use car-t therapi without use precondit agent celyad initi
open label phase think studi assess safeti activ seven differ
refractori cancer indic hematolog cancer aml multipl myeloma five solid
cancer colorect bladder pancrea triple-neg breast ovarian includ studi
design decemb celyad present data phase think trial assess
safeti clinic activ multipl dose without precondit hematolog
malign cohort relapsed/refractori r/r acut myeloid leukemia aml multipl myeloma mm
think hematolog arm r/r aml patient without precondit chemotherapi eight r/r
aml patient evalu least one cycl five eight patient
relev bm blast decreas evalu r/r aml patient three object respons previous
report one complet respons cr dose level partial hematolog recoveri
patient bridg allo-transpl month still minim residu diseas
neg cr remind typic median overal surviv similar aml patient less four
month celyad pursu studi aml patient includ stand alon agent
standard care vidaza tradit car-t therapi precondit regiment
therapeut white neutral also begun phase voyag studi
r/r aml patient nk cell cancer immunotherapi compris adapt memori nk
cell highli special function distinct subset activ nk cell high express
matur marker memory-lik activ receptor syro pharmaceut
fein neutral develop rar agonist combin therapi frontlin
r/r aml patient oryzon genom ori rate develop select inhibitor
iadademstat combin therapi elderli aml patient pharma rate
develop hdac inhibitor pracinostat combin vidaza aml patient unfit intens
chemotherapi studi mani on-going studi variou compani
institut emphas divers approach develop aml therapi highlight
selectin differenti approach aml issu patent uproleselan method use
expect expir addit pend patent applic uproleselan
and/or method use anticip last expir issu august compani
receiv notic japanes patent issuanc uproleselan composit matter pharmaceut
multipl myeloma indic broader earli pipelin support anti-selectin util
beyond scd aml appli selectin inhibit therapi multipl myeloma mm
well tumor type uproleselan phase test mm e-selectin
inhibitor phase variou tumor type compani addit explor
inhibit fibrosi oncolog preclin stage possibl signific uproleselan mm
present altern mechanist approach diseas target almost dozen approv
drug combin treatment includ chemotherapi corticosteroid proteasom inhibitor
immunostimulatori cytolyt antibodi thalidomid analogu nitrosourea dna replic
inhibit uproleselan present novel approach inhibit e-selectin would otherwis
facilit bind cancer cell vascular nich bone marrow limit cancer exposur
chemotherapi circul
multipl myeloma hematolog cancer develop plasma cell found bone marrow
overgrowth plasma cell crowd blood-form cell bone marrow lead
complic anemia bone degener anoth major problem myeloma patient
activ osteoclast fail complement osteoblast bone product lead frail bone
suscept fractur compromis level normal plasma cell infect becom concern
appropri antibodi product limit overabund myeloma cell accord
american cancer societi approxim new patient diagnos multipl myeloma
approxim death expect diseas treatment option
multipl myeloma increas significantli past ten year improv surviv rate
howev still signific unmet need provid opportun novel treatment mm
consid curabl current treatment believ uproleselan approv potenti
introduc novel clinic signific option multipl myeloma patient
glycomimet phase multipl ascend dose-escal trial e-selectin antagonist uproleselan
defin popul mm patient adjunct standard care chemotherapi underway
glycomimet interest treat patient m-protein level begin rise determin m-protein
level lower compani plan discuss mm program detail
includ therapi could possibl help transplant set proof concept data includ affect
m-protein anticip septemb announc dose first
patient phase trial uproleselan combin velcade-bas chemotherapi mm phase
trial multi-cent open-label dose escal trial measur efficaci safeti
pharmacokinet uproleselan combin chemotherapi among patient diagnos mm
respond well standard chemotherapi primari outcom measur consist safeti
assess frequenc sever related time-frame six month overal
respons rate time-frame month secondari outcom measur time frame
month includ clinic benefit rate time respons time progress durat respons
progress free surviv overal surviv time versu plasma concentr profil uproleselan
time-frame day first cycl
sever approv drug address mm diseas state differ target includ histon
deacetylas proteasom angiogenesi ubiquitin ligas dna target immun system
target mani pathway addit explor drug develop treatment
mm karyopharm white buy exampl develop selinexor combin treatment
r/r mm patient selinexor oral select inhibitor nuclear export sine compound design
select induct apoptosi cancer cell result tumor suppressor protein accumul
within cell nucleu karyopharm conduct multipl studi selinexor mm includ phase
storm studi intern multicent single-arm trial heavili pre-treat penta-refractori
myeloma patient karyopharm nda submiss fda accept acceler approv
oral selinexor low dose dexamethason patient penta-refractori multipl myeloma
previous receiv orphan drug track design fda indic
pdufa date april compani anticip submiss market author
applic ema condit approv approv compani anticip
potenti initi market launch phase boston studi evalu selinexor
combin once-weekli subcutan velcad low-dos dexamethason svd patient
receiv one three prior line therapi top-lin data expect assum
posit outcom karyopharm plan request full approv svd patient least one prior
therapi myeloma
furthermor august genmab gen co selvaraju buy announc european market
author darzalex daratumumab combin velcad melphalan prednison vmp
front-lin mm patient inelig autolog stem cell transplant addit posit
phase maia data darzalex plu celgen celg rate revlimid lenalidomid
dexamethason d-rd vs revlimid dexamethason rd transplant-inelig mm also
establish regimen potenti standard care patient popul darzalex human
monoclon antibodi mab high affin darzalex approv vmp
combin therapi front-lin mm patient inelig autolog stem cell transplant fda
approv also expect darzalex revlimid dexamethason transplant-inelig mm patient
combin therapi second third-lin mm monotherapi fourth-lin mm
glycomimet small molecul dual inhibitor e-selectin develop
target immun modul cancer chemokin receptor express variou cancer
includ hematolog cancer solid tumor intend mobil tumor cell
sensit chemotherapi alter tumor microenviron enhanc immun
respons manag note phase trial e-selectin antagon healthi
volunt complet anticip detail regard clinic trial program announc
earli purpos phase studi evalu safeti pharmacokinet
healthi adult subject studi random double-blind placebo-control singl ascend iv
dose studi across estim healthi subject safeti evalu throughout studi blood
urin collect safeti pharmacokinet evalu primari outcom
measur treatment relat advers event measur safeti toler time-frame
day accord protocol secondari outcom measur base pharmacokinet
includ peak plasma concentr auc area curv time peak plasma concentr
valuat base price target probability-adjust forecast uproleselan aml
mm well rivipansel scd voc use net present valu revenu forecast
appli po aml phase po mm phase po
scd voc phase price/sal multipl aml mm total estim uproleselan
valu valu rivipansel estim year-end net cash per share
arriv price target p/ multipl in-line peer rang
glycomimet finish cash equival compani anticip
cash equival releas uproleselan data r/r aml patient
anticip expect includ compani receiv possibl mileston
payment result rivipansel collabor interim estim
uproleselan aml patient reach market gener sale million year
million estim uproleselan mm patient reach market
gener sale million year million rivipansel scd voc
patient estim product reach market gener million mileston
royalti payment year million total royalti remind
investor novarti nv rate acquir selexi novemb approxim
includ up-front acquisit mileston payment obtain phase anti-p-selectin antibodi
develop scd voc assign valu potenti preclin earli
stage selectin galectin product view potenti upsid call option
figur phase transit success likelihood approv diseas
biom tracker amplion
factset rate wainwright research compani report
regulatori risk regulatori risk could receiv regulatori approv
uproleselan product develop could receiv approv
rivipansel collabor regulatori approv may delay
applic submit addit healthcar reform countri may impact
commerci risk commerci risk success market sell
uproleselan pipelin product receiv regulatori approv current
compani market product need build sale market medic liaison team
well establish distribut infrastructur on-going develop potenti approv
commerci rivipansel shift collabor rivipansel
risk includ physician accept adopt novel selectin inhibitor therapi govern
payor reimburs line expect potenti government price control
clinic develop risk develop risk associ preclin clinic studi
potenti delay start trial glycomimet current investig uproleselan aml mm
variou tumor type inflammatori diseas addit pipelin trial preclin stage
enrol may take signific amount time clinic trial trial may postpon delay
varieti reason addit outcom trial difficult predict could fail
number reason includ safeti efficaci relianc third parti conduct futur clinic trial
reduc control necessit contract agreement honor
manufactur risk glycomimet oper manufactur facil third-
parti contract manufactur util manufactur preclin clinic test
agreement would need implement potenti futur commerci product compani
could face issu time cost present risk well abil manufactur
consist product manufactur facil highli regul subject risk closur
financi risk glycomimet incur oper loss sinc incept view may
achiev profit sever year compani could need rais capit futur sustain
oper addit stock biotechnolog compani like publicli trade compani
subject market volatil liquid risk small trade float suscept
risk
liabil risk glycomimet product candid may caus undesir side effect
properti could result legal action taken subject trial commerci patient
compani product liabil lawsuit common biopharmaceut industri compani also
vulner typic busi liabil associ conduct busi litigi environ
intellectu properti risk maintain intellectu properti ownership exclus right
issu patent patent pend applic involv fundament featur glycomimet
therapeut method use chemic modif issu patent rivipansel method use
anticip expir issu patent uproleselan method use
expect expir addit pend patent applic uproleselan
and/or method use anticip last expir issu august compani
receiv notic japanes patent issuanc uproleselan composit matter pharmaceut
formul expir decemb biotechnolog industri litigi lawsuit consid
normal part busi court might uphold intellectu properti right
could find infring upon anoth parti properti right addit biotech firm
could potenti find loophol intellectu properti estat might enabl
launch gener version product prior expir patent protect
product unabl obtain protect intellectu properti right may abl
compet effect commerci market
compani report wainwright estim
npv/sharerevenu estimatesuproleselan present valueuproleselan payments- royalties- total revenu tax income- npv per inc
compani report wainwright estim
revenue- mileston royalti revenue- total revenue- cost expensesresearch develop gener administr total cost loss total incom net incom loss comprehens basic dilut net loss per common basic dilut weight averag number common fy inc
compani report wainwright estim
assetscash cash prepaid expens current total current properti equip prepaid research develop total liabil stockhold equitycurr liabilitiesaccount accru accru defer rent current total current defer rent net current total total stockhold total liabil stockhold fy inc
compani report wainwright estim
fy activitiesnet incom adjust reconcil net loss net cash use oper loss dispos properti stock-bas compens chang asset liabil prepaid expens current prepaid research develop expenses- deposits- account accru expens defer net cash use oper invest activitiespurchas properti net cash use invest financ activitiesproce issuanc common stock net issuanc costs- proce exercis stock option net cash provid financ net chang cash cash cash equival begin cash equival end inc
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc glyc-u
rate price target histori inc acer-u
rate price target histori celyad sa cyad-u
rate price target histori therapeut fate-u
rate price target histori inc gbt-u
rate price target histori genmab a/ gen co
rate price target histori pharmaceut plc jazz-u
rate price target histori jounc inc jnce-u
rate price target histori inc kpti-u
rate price target histori la jolla co ljpc-u
rate price target histori omero corpor omer-u
rate price target histori inc syrs-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
edward white matthew caufield certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc inc co omero corpor syro
pharmaceut inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc inc celyad sa inc genmab a/
inc inc co omero corpor syro
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst and/or research analyst household financi interest secur
pharmaceut plc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
plc
research analyst firm and/or research analyst household financi interest secur
includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc celyad sa genmab
pharmaceut inc inc invest bank servic within twelv month
seek compens compani mention report invest bank servic within three month follow
public research report
firm affili receiv compens therapeut inc global blood therapeut inc
karyopharm inc invest bank servic within twelv month seek compens
compani mention report invest bank servic within three month follow public research
 wainwright co llc manag co-manag public offer secur inc global blood
therapeut inc inc past month
firm make market inc inc celyad sa global blood
co omero corpor inc inc date
research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
